Seattle Children's Hospital spinout BrainChild Bio has raised $116 million in Series A financing to advance pediatric brain cancer CAR-T therapies. The funding will support the Phase 2 ILLUMINATE trial of lead asset BCB-276 for diffuse intrinsic pontine glioma (DIPG), a uniformly fatal childhood tumor. BCB-276 targets the B7-H3 protein and is delivered directly to the cerebrospinal fluid, avoiding pre-treatment chemotherapy and reducing systemic side effects.
BrainChild Bio Series A financing
- ▪BrainChild Bio's Series A financing round was led by an undisclosed private family fund and foundation, with participation from Seattle Children's Hospital and WRF Capital.
- ▪BrainChild Bio raised $116 million in a Series A venture financing round, as announced by the company on September 8, 2026.
- ▪BrainChild Bio was spun out of research at Seattle Children's Hospital in late 2023 to accelerate CAR-T cell therapies for children with brain tumors.
Pediatric brain cancer CAR-T
- ▪BrainChild Bio is developing autologous CAR-T cell therapies designed specifically to treat rare and deadly brain cancers in pediatric patients.
- ▪BrainChild Bio's experimental CAR-T therapy BCB-214 is in preclinical development for glioblastoma, with initial clinical testing planned to begin in 2027.
DIPG tumor characteristics
- ▪Most children diagnosed with diffuse intrinsic pontine glioma die within two years of diagnosis, and current treatments are limited to palliative focal radiation, chemotherapy, or fluid-shunting surgery.
- ▪Diffuse intrinsic pontine glioma is a rare, high-grade brain stem tumor affecting approximately 300 children in the United States annually that is uniformly fatal.
- ▪Symptoms of diffuse intrinsic pontine glioma include slurred speech, difficulty swallowing, balance problems, and drooping facial features.
BCB-276 Phase 2 trial
- ▪BrainChild Bio is conducting the Phase 2 ILLUMINATE study, an open-label, single-arm trial evaluating its lead CAR-T asset BCB-276 in newly diagnosed diffuse intrinsic pontine glioma.
- ▪The Phase 2 ILLUMINATE study of BCB-276 aims to enroll 75 patients, with topline data and primary completion expected in 2028.
B7-H3 targeted therapy mechanism
- ▪BrainChild Bio's BCB-276 is an autologous CAR-T therapy that targets B7-H3, a protein universally expressed or overexpressed in diffuse intrinsic pontine glioma.
- ▪BrainChild Bio administers BCB-276 directly into the cerebrospinal fluid to allow the CAR-T cells to directly access the tumor bed in the brain.
- ▪BrainChild Bio's BCB-214 is designed to target three cancer markers—B7-H3, EGFR, and IL13Rα2—to overcome tumor heterogeneity and function in an immunosuppressive environment.
- ▪Recipients of BCB-276 do not require a chemotherapy conditioning regimen prior to treatment, which enables multiple dosing and helps keep the re-engineered cells in the brain to lower systemic side effects.
Pediatric oncology funding challenges
- ▪BrainChild Bio Chief Scientific Officer Michael Jensen noted that few companies have tested CAR-T treatments against brain cancer due to an industry prejudice that the brain is intolerant to directly administered cells.
- ▪BrainChild Bio CEO Steven Brugger stated that financing pediatric oncology programs is historically challenging because sales opportunities in rare childhood cancers are smaller than adult cancer markets.
Debatable claims
- ▪BrainChild Bio's direct-to-brain CAR-T administration poses unacceptable safety risks
- ▪Private venture capital is an unsuitable primary funding source for rare pediatric cancer therapies
Story comments
Loading comments…